Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Kofxz (1989)
Treatment of Reflux Esophagitis with Blockers, Antacids and Prokinetic Drugs:An Analysis of Randomized Clinical TrialsScandinavian Journal of Gastroenterology, 24
K. Lloyd-Davies, K. Rutgersson, L. Sölvell (1988)
Omeprazole in the treatment of Zollinger—Ellison syndrome: a 4‐year international studyAlimentary Pharmacology & Therapeutics, 2
Herbst JJ (1981)
Gastroesophageal refluxJ Pediatr, 88
Campoli-Richards DM Clissold SP (1986)
OmeprazoleDrugs, 32
T. Havelund, L. Laursen, E. Skoubo-Kristensen, B. Andersen, S. Pedersen, K. Jensen, C. Fenger, F. Hanberg‐Sørensen, K. Lauritsen (1988)
Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trialBritish Medical Journal (Clinical research ed.), 296
S. Joelson, I. Joelson, P. Lundborg, A. Walan, M. Wallander (1992)
Safety experience from long-term treatment with omeprazole.Digestion, 51 Suppl 1
L. Lundell, L. Backman, P. Ekström, L. Enander, O. Fausa, T. Lind, H. Lönroth, S. Sandmark, B. Sandzên, P. Unge, I. Westin (1990)
Omepmazole or high‐dose ranitidine in the treatment of patients with reflux oesophagitis not responding to ‘standard doses’of H2‐receptor antagonistsAlimentary Pharmacology & Therapeutics, 4
J. Øster (1972)
RECURRENT ABDOMINAL PAIN, HEADACHE AND LIMB PAINS IN CHILDREN AND ADOLESCENTSPediatrics
D. Colin-Jones (1989)
Histamine-2-receptor antagonists in gastro-oesophageal reflux.Gut, 30
T. Gunasekaran, E. Hassall (1993)
Efficacy and safety of omeprazole for severe gastroesophageal reflux in children.The Journal of pediatrics, 123 1
F. Epstein, M. Wolfe, A. Soll (1988)
The physiology of gastric acid secretion.The New England journal of medicine, 319 26
Dahms BB Kilbridge PM (1988)
Campylobacter pylori-associated gastritis and peptic ulcer disease in childrenAJDC, 142
H. Koelz (1989)
Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials.Scandinavian journal of gastroenterology. Supplement, 156
A. Dalzell, J. Searle, M. Patrick (1992)
Treatment of refractory ulcerative oesophagitis with omeprazole.Archives of Disease in Childhood, 67
L. Hixson, C. Kelley, W. Jones, C. Tuohy (1992)
Current trends in the pharmacotherapy for gastroesophageal reflux disease.Archives of internal medicine, 152 4
S. Kato, H. Shibuya, Y. Hayashi, S. Tseng, H. Nakagawa, R. Ohi (1992)
Effectiveness and pharmacokinetics of omeprazole in children with refractory duodenal ulcer.Journal of pediatric gastroenterology and nutrition, 15 2
T. Lind, C. Cederberg, G. Ekenved, U. Haglund, L. Olbe (1983)
Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.Gut, 24
Peter Kilbridge, Beverly Dahms, S. Czinn (1988)
Campylobacter pylori--associated gastritis and peptic ulcer disease in children.American journal of diseases of children, 142 11
R. Gugler, Guntram Fuchs, Michael Dieckmann, A. Somogyi (1981)
Cimetidine plasma concentration‐response relationshipsClinical Pharmacology & Therapeutics, 29
J. Apley, N. Naish (1958)
Recurrent Abdominal Pains: A Field Survey of 1,000 School ChildrenArchives of Disease in Childhood, 33
Johanessen T (1985)
Function and Disease of the Esophagus
K. Bardhan (1993)
Is there any acid peptic disease that is refractory to proton pump inhibitors ?Alimentary Pharmacology & Therapeutics, 7
Rutgersts L Vantrappen G (1988)
Omeprazole (40 milligrams) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitisDig Dis Sci, 33
M. Feldman, Burton Me (1990)
Histamine 2-receptor antagonists--standard therapy for acid-peptic diseases.The New England journal of medicine, 324 18
S. Sontag (1993)
Rolling review: gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 7
Tytgat GNJ De Boer WA (1994)
Review article: drug therapy for reflux esophagitisAliment Pharmacol Ther, 8
Jansen KMBJ Klinkenberg-Knol EC (1987)
Double blind multicenter comparison of omeprazole and ranitidine in the treatment of reflux esophagitisLancet, 1
J. Blumer, F. Rothstein, B. Kaplan, T. Yamashita, F. Eshelman, C. Myers, M. Reed (1985)
Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease.The Journal of pediatrics, 107 2
Laursen L Havelund T (1988)
Omeprazole and ranitidine in treatment of reflux esophagitis: double blind comparative trialBMJ, 296
E. Fellenius, B. Elander, B. Wallmark, H. Helander, T. Berglindh (1982)
Inhibition of acid secretion in isolated gastric glands by substituted benzimidazoles.The American journal of physiology, 243 6
Becker M Somogyi A (1985)
Cimetidine pharmacokinetics and dosage requirements in childrenEur J Pediatr, 144
H. Koop, J. Hotz, G. Pommer, M. Klein, R. Arnold (1990)
Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2‐receptor antagonistsAlimentary Pharmacology & Therapeutics, 4
W. Balistreri, M. Farrell (1983)
Gastroesophageal reflux in infants.The New England journal of medicine, 309 13
P. Farup (1992)
Compliance with anti‐ulcer medication during short‐term healing phase clinical trialsAlimentary Pharmacology & Therapeutics, 6
M. Collen, J. Lewis, S. Benjamin (1990)
Gastric acid hypersecretion in refractory gastroesophageal reflux disease.Gastroenterology, 98 3
L. Olbe, T. Lind, C. Cederberg, G. Ekenved (1986)
Effect of omeprazole on gastric acid secretion in man.Scandinavian journal of gastroenterology. Supplement, 118
Abstract Objective: To evaluate the cause of chronic abdominal pain lasting more than 3 weeks in 153 patients aged 6 to 18 years (mean, 9.9 years) who had undergone endoscopy. Design: Those patients with peptic esophagitis as the cause of their chronic pain were treated with high-dose ranitidine hydrochloride, followed by the proton-pump inhibitor, omeprazole, for those who did not respond to a histamine2-receptor antagonist. Results: Eighty-four percent of patients had peptic esophagitis, 3% had Helicobacater pylori gastritis, and 3% had ulcer disease. Seventy percent of the patients with peptic esophagitis responded to an 8-week course of high-dose ranitidine hydrochloride (4 mg/kg per dose, twice a day or three times a day). Of the 30% of patients who failed to respond to ranitidine therapy, 87% responded to an 8-week course of omeprazole (20 mg/d). The grade of esophagitis at initial endoscopy was a predictive factor for response to ranitidine therapy. Ninety percent of patients with grade 1 esophagitis responded to ranitidine therapy vs only 43% of those with grade 3 or 4 esophagitis. Only five patients (4%) failed to respond to both therapies; three of these subsequently underwent Nissen fundoplications. There were no side effects of either ranitidine or omeprazole therapy. Conclusions: These findings indicate that (1) peptic esophagitis was a common cause of chronic abdominal pain in pediatric patients and (2) omeprazole was effective in the treatment of esophagitis in children and adolescents that was resistant to high-dose histamine2receptor antagonists.(Arch Pediatr Adolesc Med. 1995;149:267-271) References 1. Apley J, Naish N. Recurrent abdominal pains: a field survey of 1000 school children . Arch Dis Child . 1958;33:165-170.Crossref 2. Oster J. Recurrent abdominal pain, headaches, and limb pains in children and adolescents . Pediatrics . 1972;50:429-436. 3. Johanessen T. Symptoms of esophagitis in general practice . In: Sanberg N, Walen A, eds. Function and Disease of the Esophagus . Philadelphia, Pa: Smith Kline & French; 1985:77-78. 4. Feldman M, Burton ME. Histamine 2 receptor antagonist: standard therapy for acid-peptic disease . N Engl J Med . 1990;323:1672-1680.Crossref 5. Koelz HR. Treatment of reflux esophagitis with H2-blockers antacids and prokinetic drugs: an analysis of randomized clinical trials . Scand J Gastroenterol . 1989;24( (suppl 156) ):25-36. 6. Klinkenberg-Knol EC, Jansen KMBJ, Fosten HMP, Meuwissen SGM, Lamers CBHW. Double blind multicenter comparison of omeprazole and ranitidine in the treatment of reflux esophagitis . Lancet . 1987:1:349-351.Crossref 7. Vantrappen G, Rutgersts L, Schurmans P, Coenegrachts JL. Omeprazole (40 milligrams) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis . Dig Dis Sci . 1988;33:523-529.Crossref 8. Havelund T, Laursen L, Skoubo-Kristensen E, et al. Omeprazole and ranitidine in treatment of reflux esophagitis: double blind comparative trial . BMJ . 1988; 296:89-92.Crossref 9. Koop H, Hotz J, Pommer G, Kllein M, Arnold R. Prospective evaluation of omeprazole treatment in reflux esophagitis refractory to H2-receptor antagonists . Aliment Pharmacol Ther . 1990;4:593-599.Crossref 10. Lloyd-Davies KA, Rutgersson K, Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study . Aliment Pharmacol Ther . 1988; 2:13-32.Crossref 11. Kato S, Shibuya H, Hayashi Y, Tseng SW, Nakagawa H, Ohi R. Effectiveness 12. Apley J, Naish N. Recurrent abdominal pains: a field survey of 1000 school children . Arch Dis Child . 1958;33:165-170.Crossref 13. Oster J. Recurrent abdominal pain, headaches, and limb pains in children and adolescents . Pediatrics . 1972;50:429-436. 14. Johanessen T. Symptoms of esophagitis in general practice . In: Sanberg N, Walen A, eds. Function and Disease of the Esophagus . Philadelphia, Pa: Smith Kline & French; 1985:77-78. 15. Feldman M, Burton ME. Histamine 2 receptor antagonist: standard therapy for acid-peptic disease . N Engl J Med . 1990;323:1672-1680.Crossref 16. Koelz HR. Treatment of reflux esophagitis with H2-blockers antacids and prokinetic drugs: an analysis of randomized clinical trials . Scand J Gastroenterol . 1989;24( (suppl 156) ):25-36. 17. Klinkenberg-Knol EC, Jansen KMBJ, Fosten HMP, Meuwissen SGM, Lamers CBHW. Double blind multicenter comparison of omeprazole and ranitidine in the treatment of reflux esophagitis . Lancet . 1987:1:349-351.Crossref 18. Vantrappen G, Rutgersts L, Schurmans P, Coenegrachts JL. Omeprazole (40 milligrams) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis . Dig Dis Sci . 1988;33:523-529.Crossref 19. Havelund T, Laursen L, Skoubo-Kristensen E, et al. Omeprazole and ranitidine in treatment of reflux esophagitis: double blind comparative trial . BMJ . 1988; 296:89-92.Crossref 20. Koop H, Hotz J, Pommer G, Kllein M, Arnold R. Prospective evaluation of omeprazole treatment in reflux esophagitis refractory to H2-receptor antagonists . Aliment Pharmacol Ther . 1990;4:593-599.Crossref 21. Lloyd-Davies KA, Rutgersson K, Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study . Aliment Pharmacol Ther . 1988; 2:13-32.Crossref 22. Kato S, Shibuya H, Hayashi Y, Tseng SW, Nakagawa H, Ohi R. Effectiveness and pharmacokinetics of omeprazole in children with refractory duodenal ulcer . J Pediatr Gastroenterol Nutr . 1992;15:184-188.Crossref 23. Dalzell AM, Searle JW, Patrick MK. Treatment of refractory ulcerative esophagitis with omeprazole . Arch Dis Child . 1992;67:641-642.Crossref 24. Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children . J Pediatr . 1993;123:148-154.Crossref 25. Kilbridge PM, Dahms BB, Czinn SJ. Campylobacter pylori-associated gastritis and peptic ulcer disease in children . AJDC . 1988;142:1149-1152. 26. Herbst JJ. Gastroesophageal reflux . J Pediatr . 1981;88:859-870.Crossref 27. Baslisteri WF, Ferrell MK. Gastroesophageal reflux in infants . N Engl J Med . 1983;309:790-792.Crossref 28. Hixson LJ, Kelley CL, Jones WN, Tuohy CD. Current trends in the pharmacotherapy of gastroesophageal reflux disease . Arch Intern Med . 1992;152:714-723.Crossref 29. Sontag SJ. Rolling review: gastro-esophageal reflux disease . Aliment Pharmacol Ther . 1993;7:293-312.Crossref 30. Colin-Jones DG. Histamine receptor antagonists in gastroesophageal reflux . Gut . 1989;30:1305-1308.Crossref 31. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease . Gastroenterology . 1990;98:654-661. 32. Somogyi A, Becker M, Gugler. Cimetidine pharmacokinetics and dosage requirements in children . Eur J Pediatr . 1985;144:72-76.Crossref 33. Blumer JL, Rothstein FC, Kaplan BS, et al. Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease . J Pediatr . 1985:107: 301-306.Crossref 34. Lundell L, Backman L, Ekstrom P, et al. Omeprazole or high-dose ranitidine in the treatment of patients with reflux esophagitis not responding to standard doses of H2-receptor antagonists . Aliment Pharmacol Ther . 1990;4:145-155.Crossref 35. Wolf MM, Soil AH. The physiology of gastric acid secretion . N Engl J Med . 1988;319:1705-1715. 36. Fellenius E, Elander B, Wallmark B, Helander HF, Berglindh T. Inhibition of acid secretion in isolated gastric glands by substituted benzimidazoles . Am J Physiol . 1982;243:G505-G510. 37. Clissold SP, Campoli-Richards DM. Omeprazole . Drugs . 1986;32:15-47.Crossref 38. Olbe L, Lind T, Cederberg C, Ekenved G. Effect of omeprazole on gastric acid secretion in man . Scand J Gastroenterol . 1986;18( (suppl 21) ):105-107.Crossref 39. Gugler R, Fuchs G, Dieckmann M, Somogyi AA. Cimetidine plasma concentrations-response relationships . Clin Pharmacol Ther . 1981;29:744-748.Crossref 40. Lind T, Cederberg C, Ekvenved G, Haglund U, Olbe L. Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man . Gut . 1983:24:270-276.Crossref 41. Bardham KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther . 1993;7( (suppl 1) ):13-24.Crossref 42. Farup PG. Compliance with anti-ulcer medication during short term healing phase clinical trials . Aliment Pharmacol Ther . 1992;6:179-186.Crossref 43. De Boer WA, Tytgat GNJ. Review article: drug therapy for reflux esophagitis . Aliment Pharmacol Ther . 1994;8:147-157.Crossref 44. Joelson S, Joelson IB, Lungdorg P, Walan A, Wallander MA. Safety experience from long-term treatment with omeprazole . Digestion . 1992;51( (suppl 1) ):93-101.Crossref 45. McTavish D, Buckley MM, Heel RC. Omeprazole. Drugs . 1991;42:138-170.Crossref
Archives of Pediatrics & Adolescent Medicine – American Medical Association
Published: Mar 1, 1995
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.